Deutsche Bank Ag\ Inozyme Pharma, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 31,160 shares of INZY stock, worth $87,559. This represents 0.0% of its overall portfolio holdings.

Number of Shares

31,160

Previous 17,699 76.06%

Holding current value

$87,559

Previous $78,000 107.69%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$4.31 - $6.0 $58,016 - $80,766	13,461 Added 76.06%	31,160 $162,000
Q2 2024 Aug 14, 2024	BUY	$4.33 - $7.31 $9,889 - $16,696	2,284 Added 14.82%	17,699 $78,000
Q1 2024 May 15, 2024	SELL	$4.14 - $7.66 $3,390 - $6,273	-819 Reduced 5.04%	15,415 $118,000
Q3 2023 Nov 09, 2023	BUY	$4.09 - $7.0 $66,397 - $113,638	16,234 New	16,234 $68,000
Q2 2022 Aug 11, 2022	SELL	$3.2 - $5.96 $24,992 - $46,547	-7,810 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$3.87 - $7.55 $3,552 - $6,930	-918 Reduced 10.52%	7,810 $32,000
Q4 2021 Feb 11, 2022	BUY	$5.58 - $11.5 $2,522 - $5,198	452 Added 5.46%	8,728 $60,000
Q3 2021 Nov 04, 2021	SELL	$11.12 - $19.4 $2,957 - $5,160	-266 Reduced 3.11%	8,276 $96,000
Q2 2021 Aug 11, 2021	BUY	$15.19 - $21.2 $9,250 - $12,910	609 Added 7.68%	8,542 $146,000
Q1 2021 May 13, 2021	BUY	$17.77 - $27.9 $31,754 - $49,857	1,787 Added 29.08%	7,933 $157,000
Q4 2020 Feb 16, 2021	BUY	$19.95 - $27.55 $34,234 - $47,275	1,716 Added 38.74%	6,146 $127,000
Q3 2020 Nov 12, 2020	BUY	$17.54 - $30.2 $77,702 - $133,786	4,430 New	4,430 $116,000

Others Institutions Holding INZY

# of Institutions

Shares Held

53M

Call Options Held

3.7K

Put Options Held

5.8K

View Full List

About Inozyme Pharma, Inc.

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $113M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

More about INZY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account